The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1 study of PARP inhibitor (niraparib) plus HSP90 inhibitor (pimitespib) in solid tumors: Dose-expansion results from the NiraPim (EPOC2102) study.
 
Yasuyuki Kawamoto
Honoraria - AstraZeneca; Incyte; Lilly Japan; Merck; MSD K.K; Nihon Servier; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - Taiho Pharmaceutical
Research Funding - Japan Agency for Medical Research and Development; Takeda
 
Hiromichi Nakajima
Employment - Otsuka (I)
Honoraria - AstraZeneca; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Pfizer; Sanofi/Regeneron; Taiho Pharmaceutical; Takeda
 
Yoshito Komatsu
Honoraria - Asahi Kasei; Bayer Yakuhin; Bristol-Myers Squibb Co.; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Medical Review Co., Ltd.; Merck; Mitsubishi Tanabe Pharma; Moroo Co.; Nipro Corporation; Ono Pharmaceutical; Otsuka; Sanofi/Aventis; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - A2 Healthcare; Astellas Pharma; Bayer Yakuhin; BeiGene (Inst); DAIICHI SANKYO CO., LTD.; Eisai; Incyte; IQvia; Lilly (Inst); Mediscience Planning; MSD K.K.; NanoCarrier; Nipro Corporation (Inst); Ono Pharmaceutical; Parexel International Corporation.; Sanofi/Aventis; Shionogi; Sumitomo Dainippon Pharma Co., Ltd.; Sysmex; Taiho Pharmaceutical; Yakult Honsha
 
Hitomi Kubota
Employment - Astellas Pharma (I)
 
Kazuko Tsukamoto
No Relationships to Disclose
 
Koji Takahashi
No Relationships to Disclose
 
Keiko Kobayashi
No Relationships to Disclose
 
Haruru Kotani
No Relationships to Disclose
 
Fumikata Hara
Honoraria - Chugai Pharma; Daiichi Sankyo; Kyowa Kirin; Lilly Japan; MSD; Pfizer; Taiho Pharmaceutical
 
Taigo Kato
Honoraria - Bristol-Myers Squibb Japan; Merck; MSD; Pfizer; Takeda
Research Funding - Takeda
 
Norio Nonomura
Honoraria - Astellas Pharma; AstraZeneca; Asuka Seiyaku; Bayer; Bristol-Myers Squibb; Chugai Pharma; Eisai; Janssen; Kissei Pharmaceutical; Kyorin; MSD; Nippon Shinyaku; Ono Pharmaceutical; Pfizer; Takeda
Research Funding - Nippon Shinyaku (Inst)
 
Takashi Ikeno
No Relationships to Disclose
 
Masashi Wakabayashi
Honoraria - Nihon Medi-Physics
 
Akihiro Sato
Honoraria - Astellas Pharma; AstraZeneca; Dainippon Sumitomo Pharma
Research Funding - Aspyerian Therapeutics (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); MSD (Inst); Oncolys BioPharma (Inst); Ono Pharmaceutical (Inst); Pentax Medical Devices (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Yoichi Naito
Consulting or Advisory Role - AstraZeneca; Bayer; Chugai Pharma; Daiichi Sankyo; Gilead Sciences; Gilead Sciences; Lilly; Pfizer; Taiho Pharmaceutical; Takeda
Speakers' Bureau - AstraZeneca; Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Eisai; FUJIFILM Toyama Chemistry; Gilead Sciences; Guardant Health; Hisamitsu Pharmaceutical; Lilly; MSD; Mundipharma; Novartis; Ono Yakuhin; Pfizer; Shionogi; Taiho Pharmaceutical; Takeda
Research Funding - Abbvie; AstraZeneca Japan; Boehringer Ingelheim; Chugai/Roche; Daiichi Sankyo; Eisai; Gilead Sciences; Lilly; Pfizer; Taiho Pharmaceutical; Takeda